Morgan Stanley Fusion Pharmaceuticals Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$7.9 - $21.32 $2.35 Million - $6.35 Million	298,034 New	298,034 $6.35 Million
Q1 2024 Aug 16, 2024	BUY	$7.9 - $21.32 $717,643 - $1.94 Million	90,841 Added 43.84%	298,034 $6.35 Million
Q1 2024 May 15, 2024	BUY	$7.9 - $21.32 $717,643 - $1.94 Million	90,841 Added 43.84%	298,034 $6.35 Million
Q4 2023 Aug 16, 2024	BUY	$2.48 - $9.65 $513,838 - $2 Million	207,193 New	207,193 $1.99 Million
Q4 2023 Feb 13, 2024	BUY	$2.48 - $9.65 $102,009 - $396,933	41,133 Added 24.77%	207,193 $1.99 Million
Q3 2023 Nov 15, 2023	BUY	$2.37 - $4.63 $67,424 - $131,718	28,449 Added 20.67%	166,060 $431,000
Q2 2023 Aug 14, 2023	BUY	$3.47 - $5.33 $67,234 - $103,274	19,376 Added 16.39%	137,611 $642,000
Q1 2023 May 15, 2023	BUY	$3.03 - $5.13 $31,169 - $52,772	10,287 Added 9.53%	118,235 $445,000
Q4 2022 Feb 14, 2023	BUY	$2.1 - $3.34 $65,669 - $104,445	31,271 Added 40.78%	107,948 $340,000
Q3 2022 Nov 14, 2022	BUY	$2.0 - $3.56 $35,710 - $63,563	17,855 Added 30.35%	76,677 $231,000
Q2 2022 Oct 27, 2022	SELL	$2.49 - $7.86 $112,448 - $354,957	-45,160 Reduced 43.43%	58,822 $146,000
Q2 2022 Aug 15, 2022	SELL	$2.49 - $7.86 $112,448 - $354,957	-45,160 Reduced 43.43%	58,822 $146,000
Q1 2022 Oct 27, 2022	BUY	$4.53 - $8.57 $204,574 - $387,021	45,160 Added 76.77%	103,982 $808,000
Q1 2022 May 13, 2022	BUY	$4.53 - $8.57 $119,469 - $226,016	26,373 Added 33.98%	103,982 $808,000
Q4 2021 Feb 14, 2022	SELL	$4.17 - $7.78 $19,503 - $36,387	-4,677 Reduced 5.68%	77,609 $324,000
Q3 2021 Nov 15, 2021	BUY	$7.83 - $9.41 $644,299 - $774,311	82,286 New	82,286 $651,000

Others Institutions Holding FUSN

# of Institutions

Shares Held

93K

Call Options Held

1.4K

Put Options Held

View Full List

About Fusion Pharmaceuticals Inc.

Ticker FUSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,390,500
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...

More about FUSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account